Who are Rasagiline mesylate with Requip's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rasagiline-mesylate-with-requip.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Rasagiline mesylate with Requip — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rasagiline mesylate with Requip (Rasagiline mesylate with Requip) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MAO-B inhibitor combined with dopamine receptor agonist. Area: Neurology.

marketed MAO-B inhibitor combined with dopamine receptor agonist MAO-B and dopamine D2/D3 receptors Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Rasagiline mesylate with Requip (Rasagiline mesylate with Requip) — Teva Neuroscience, Inc.. Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while ropinirole (Requip) is a dopamine D2/D3 receptor agonist, together enhancing dopaminergic signaling for Parkinson's disease management.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rasagiline mesylate with Requip TARGET	Rasagiline mesylate with Requip	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine receptor agonist	MAO-B and dopamine D2/D3 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MAO-B inhibitor combined with dopamine receptor agonist class)

Teva Neuroscience, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rasagiline mesylate with Requip — Competitive Intelligence Brief. https://druglandscape.com/ci/rasagiline-mesylate-with-requip. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab